Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer
NCT ID: NCT03381352
Last Updated: 2018-01-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
27 participants
INTERVENTIONAL
2015-12-02
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma
NCT00973778
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
NCT05507112
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC
NCT06599827
Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer
NCT01871363
Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
NCT05374252
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chemo-radiotherapy with IMRT technique
Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy
Chemo-radiotherapy with IMRT technique
IMRT radiation technique; 50.4-54Gy/25F
Capecitabine
Capecitabine 825mg/m2 PO BID
Mitomycin C
Mitomycin C 10mg/m2 D1,29 iv
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemo-radiotherapy with IMRT technique
IMRT radiation technique; 50.4-54Gy/25F
Capecitabine
Capecitabine 825mg/m2 PO BID
Mitomycin C
Mitomycin C 10mg/m2 D1,29 iv
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed anal squamous carcinoma;
* KPS \>= 70
* Adequate organ function;
* No previous radiotherapy or chemotherapy;
* No surgery.
Exclusion Criteria
* Allegic to 5-fu or MMC
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
LI Ning
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chinese academy of medical sciences
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Y-MX2015-014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.